New treatments for macular degeneration may ... RGX-314 gene therapy only requires one injection, but it must be performed via a surgical procedure. This treatment is currently moving through ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Neovascular age-related macular degeneration (AMD), also known as ... injection of special drugs into the affected eye(s). Laser therapy is sometimes combined with these drugs.

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating individuals with macular oedema following retinal vein ...

Janet Osborne hopes to continue gardening if her sight loss is halted A woman from Oxford has become the first person in the world to have gene therapy to try to halt the most common form of ...

Visual prognosis depends on the type of retinal vein occlusion, its severity, degree of retinal ischemia or macular edema (ME ... The introduction of anti-VEGF therapy has altered treatment ...

The implant is surgically inserted during a one-time outpatient procedure and provides continuous ... age-related macular degeneration in patients who have previously responded to at least 2 ...